- |||||||||| LY 3475070 / Eli Lilly
Enrollment closed, Trial completion date, Combination therapy, Monotherapy, Metastases: KEYNOTE A57: A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer (clinicaltrials.gov) - May 19, 2021 P1, N=150, Active, not recruiting, Trial completion date: Dec 2021 --> Jun 2022 Recruiting --> Active, not recruiting | Trial completion date: Dec 2022 --> Dec 2021
|